Diffusion Pharmaceuticals Inc. (DFFN), a clinical stage biotechnology company focused on the development of novel small molecule therapeutics for cancer and other hypoxia related diseases, today announced that its Board of Directors approved an amendment to the Company’s certificate of
incorporation effecting a 1 for 10 reverse split of all outstanding common stock.
Diffusion Pharmaceuticals Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market
This entry was posted in Recent Development News: Q3 - 2016, Recent Developments. Bookmark the permalink.
